Home / Market News / $VVOS
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Vivos Therapeutics Confirms Compliance with Nasdaq Listing Standards

Oct 21, 2026, 6:04 PM UTC · Primary ticker $VVOS

Vivos Therapeutics announced it has regained compliance with Nasdaq's shareholders' equity standard, resolving a previous listing issue. This ensures the company's continued listing on the Nasdaq exchange, removing a significant delisting risk.

Vivos Therapeutics received formal notification from Nasdaq confirming its compliance with the shareholders' equity standard. This is significant because the company had a previous compliance issue regarding its financial standing, which put its Nasdaq listing at risk. The resolution of this issue removes the immediate threat of delisting, which is a positive development for current shareholders and potential investors. In the short term, this news alleviates uncertainty and could lead to a modest positive sentiment. Long-term implications are neutral as it simply maintains the status quo, but it removes a significant overhang that could have deterred investment. The key opportunity for traders is the removal of a downside risk, potentially stabilizing the stock.

$VVOS positive Resolved delisting risk
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.